On June 17, 2025, Citius Oncology, Inc. announced they are close to launching LYMPHIR™, an FDA-approved treatment for relapsed or refractory cutaneous T-cell lymphoma (CTCL). This is a significant milestone for the company as they prepare for this commercial release.